Cargando…
Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia
Chemoresistance often complicates the management of cancer, as noted in the instance of acute myeloid leukemia (AML). Mitochondrial function is considered important for the viability of AML blasts and appears to also modulate chemoresistance. As mitochondrial metabolism is aberrant in AML, any disti...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513429/ https://www.ncbi.nlm.nih.gov/pubmed/37746249 http://dx.doi.org/10.3389/fonc.2023.1244280 |
_version_ | 1785108568605720576 |
---|---|
author | Feng, Lili Zhang, Philip Y. Gao, Wenda Yu, Jinming Robson, Simon C. |
author_facet | Feng, Lili Zhang, Philip Y. Gao, Wenda Yu, Jinming Robson, Simon C. |
author_sort | Feng, Lili |
collection | PubMed |
description | Chemoresistance often complicates the management of cancer, as noted in the instance of acute myeloid leukemia (AML). Mitochondrial function is considered important for the viability of AML blasts and appears to also modulate chemoresistance. As mitochondrial metabolism is aberrant in AML, any distinct pathways could be directly targeted to impact both cell viability and chemoresistance. Therefore, identifying and targeting those precise rogue elements of mitochondrial metabolism could be a valid therapeutic strategy in leukemia. Here, we review the evidence for abnormalities in mitochondria metabolic processes in AML cells, that likely impact chemoresistance. We further address several therapeutic approaches targeting isocitrate dehydrogenase 2 (IDH2), CD39, nicotinamide phosphoribosyl transferase (NAMPT), electron transport chain (ETC) complex in AML and also consider the roles of mesenchymal stromal cells. We propose the term “mitotherapy” to collectively refer to such regimens that attempt to override mitochondria-mediated metabolic reprogramming, as used by cancer cells. Mounting evidence suggests that mitotherapy could provide a complementary strategy to overcome chemoresistance in liquid cancers, as well as in solid tumors. |
format | Online Article Text |
id | pubmed-10513429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105134292023-09-22 Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia Feng, Lili Zhang, Philip Y. Gao, Wenda Yu, Jinming Robson, Simon C. Front Oncol Oncology Chemoresistance often complicates the management of cancer, as noted in the instance of acute myeloid leukemia (AML). Mitochondrial function is considered important for the viability of AML blasts and appears to also modulate chemoresistance. As mitochondrial metabolism is aberrant in AML, any distinct pathways could be directly targeted to impact both cell viability and chemoresistance. Therefore, identifying and targeting those precise rogue elements of mitochondrial metabolism could be a valid therapeutic strategy in leukemia. Here, we review the evidence for abnormalities in mitochondria metabolic processes in AML cells, that likely impact chemoresistance. We further address several therapeutic approaches targeting isocitrate dehydrogenase 2 (IDH2), CD39, nicotinamide phosphoribosyl transferase (NAMPT), electron transport chain (ETC) complex in AML and also consider the roles of mesenchymal stromal cells. We propose the term “mitotherapy” to collectively refer to such regimens that attempt to override mitochondria-mediated metabolic reprogramming, as used by cancer cells. Mounting evidence suggests that mitotherapy could provide a complementary strategy to overcome chemoresistance in liquid cancers, as well as in solid tumors. Frontiers Media S.A. 2023-09-07 /pmc/articles/PMC10513429/ /pubmed/37746249 http://dx.doi.org/10.3389/fonc.2023.1244280 Text en Copyright © 2023 Feng, Zhang, Gao, Yu and Robson https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Feng, Lili Zhang, Philip Y. Gao, Wenda Yu, Jinming Robson, Simon C. Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia |
title | Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia |
title_full | Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia |
title_fullStr | Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia |
title_full_unstemmed | Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia |
title_short | Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia |
title_sort | targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513429/ https://www.ncbi.nlm.nih.gov/pubmed/37746249 http://dx.doi.org/10.3389/fonc.2023.1244280 |
work_keys_str_mv | AT fenglili targetingchemoresistanceandmitochondriadependentmetabolicreprogramminginacutemyeloidleukemia AT zhangphilipy targetingchemoresistanceandmitochondriadependentmetabolicreprogramminginacutemyeloidleukemia AT gaowenda targetingchemoresistanceandmitochondriadependentmetabolicreprogramminginacutemyeloidleukemia AT yujinming targetingchemoresistanceandmitochondriadependentmetabolicreprogramminginacutemyeloidleukemia AT robsonsimonc targetingchemoresistanceandmitochondriadependentmetabolicreprogramminginacutemyeloidleukemia |